Treats heartburn and other symptoms associated GERD. ANDA 211977, held by Hetero Labs Ltd Iii. Esomeprazole Magnesium.
As of Nov 16, 2026, ANDA 211977 (Esomeprazole Magnesium), held by Hetero Labs Ltd Iii, was first approved by FDA on Jun 2, 2020, with 3 approved supplements and 0 published complete response letters.
Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: · Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. · Maintenance of healing of EE in adults. · Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. · Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 2, 2020 | Original application | Approved | None posted |
| Esomeprazole MagnesiumEQ 20MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| Esomeprazole MagnesiumEQ 40MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| Nov 14, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 27, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 27, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 2, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters